Absci Corporation, a trailblazer in generative AI for drug creation, has announced a pivotal collaboration with AMD, leveraging AMD Instinct™ accelerators and ROCm™ software to power Absci's AI-driven drug discovery processes. Central to this partnership is AMD's $20 million private investment in public equity (PIPE), highlighting a surging demand for innovative applications of AI in biopharma.

This partnership aims to supercharge Absci's mission to create better biologics faster by integrating high-performance computing solutions optimized for complex biological modeling. The collaboration promises reduced infrastructure costs, faster innovation cycles, and unmatched performance for Absci's proprietary models, including IgDesign1—the first in vitro validated inverse folding model for antibody design.

Absci Founder & CEO Sean McClain will unveil more details about this transformative partnership at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th at 4:30 PM PT.

A Powerful Alliance for Biopharma Innovation

"At Absci, we are always looking for ways to push the boundaries of what’s possible in drug discovery," said Sean McClain. "This partnership with AMD gives us the unique advantage of working with a partner that is deeply committed to supporting our needs while providing the most efficient, innovative AI solutions available. AMD's high-performance compute capabilities will enable us to advance next-generation antibody therapeutics, accelerating the future of drug discovery."

AMD’s executive leadership echoed this sentiment, emphasizing the synergies between Absci’s cutting-edge AI models and AMD’s advanced hardware. "We are proud to partner with Absci, a company at the forefront of AI-driven drug discovery, to help further accelerate breakthroughs in therapeutics and transform how biologic drugs are developed," said Mark Papermaster, AMD's Executive Vice President and Chief Technology Officer. "Absci’s groundbreaking work in AI drug discovery is a perfect fit for AMD high-performance computing solutions and software, designed for the most demanding AI workloads."

Breaking Barriers in Antibody Design

The collaboration represents a milestone for both companies. Absci’s focus on generative AI for de novo antibody design aligns seamlessly with AMD’s expertise in high-performance computing, creating a powerful ecosystem for innovation in biologics. The use of AMD Instinct accelerators promises to unlock new potential in drug discovery, streamlining workflows and expanding the capabilities of Absci’s AI models.

As Absci and AMD join forces, the future of AI-driven drug discovery looks more promising than ever—paving the way for groundbreaking therapeutics that can improve lives at unprecedented speed.